olivLaw · European equity research
Medistim Asa MEDI.OL
Norway · Euronext Oslo Børs · ISIN NO0010159684 · Vertical: Listed companies from Norway
At the close of 06 Nov 2026, Medistim Asa (MEDI.OL) stock was 306.00 NOK (+0.00% on the day), with market capitalisation 5.6 bn NOK, P/E 35.1 on diluted EPS of 8.71 NOK over the last 12 months, dividend yield 1.96%, beta 0.46, 52-week range 188.00–308.00 NOK.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 66.2
- strong (55–70)
- Bollinger (20, 2)
- 271.97 – 317.63
- in the upper half of the band · %B 0.75 · band width 15.5%
- SMA 50 / 200
- 270.14 / 237.77
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 11.07 / 11.75
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +14.2% | −0.2% | +14.3 pp | — |
| 3 months | +34.2% | −5.4% | +39.6 pp | — |
| 6 months | +35.4% | +4.4% | +31.0 pp | — |
| Year to date | +18.1% | +6.5% | +11.7 pp | — |
| 1 year | +22.4% | +10.0% | +12.4 pp | −4.7% |
| 3 years | +45.7% | +48.6% | −2.9 pp | +12.7% |
| 5 years | −19.5% | +41.4% | −60.9 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 67 percentile of its own 3-quarter history (min 26.4, median 29.7, max 37.7; quarters with earnings only).
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 521.1 m | 562.6 m | 699.8 m |
| Revenue YoY | unavailable | +8.0% | +24.4% |
| Net income | 103.8 m | 103.8 m | 159.2 m |
| Net income YoY | unavailable | +0.0% | +53.3% |
| Diluted EPS | 5.67 | 5.67 | 8.71 |
| Diluted EPS YoY | unavailable | 0.0% | +53.6% |
| net % | 19.9% | 18.5% | 22.8% |
| Free cash flow | 102.8 m | 137.0 m | 181.6 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 212.1 m NOK
- Financial debt
- unavailable NOK
- Net debt
- unavailable NOK
- Equity
- 468.4 m NOK
- Total assets
- 660.6 m NOK
- Debt / equity
- unavailable
- Current ratio
- 3.34x
- ROE
- 35.2%
- ROA
- 25.8%
- FCF margin
- 26.0%
Financial statements (source on every figure)
Revenue and net income (NOK)
Margins
Income statement · NOK
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 521.1 m | 562.6 m | 699.8 m | esef· 21 Oct 2026verified |
| Operating income | 131.4 m | 131.1 m | 196.2 m | esef· 21 Oct 2026verified |
| Depreciation & amortisation | 23.7 m | 24.5 m | 24.8 m | esef· 21 Oct 2026verified |
| EBITDA | 155.1 m ≈ | 155.6 m ≈ | 221.0 m ≈ | esef· 21 Oct 2026derived |
| Interest expense | 13.4 m | 8.3 m | 16.8 m | esef· 21 Oct 2026verified |
| Pre-tax income | 135.2 m | 134.2 m | 206.8 m | esef· 21 Oct 2026verified |
| Income tax | 31.4 m | 30.4 m | 47.6 m | esef· 21 Oct 2026verified |
| Net income | 103.8 m | 103.8 m | 159.2 m | esef· 21 Oct 2026verified |
| Diluted EPS | 5.67 | 5.67 | 8.71 | esef· 21 Oct 2026verified |
| Dividend per share | 4.50 | 6.00 | 6.00 | esef· 21 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · NOK
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 153.9 m | 179.2 m | 212.1 m | esef· 21 Oct 2026verified |
| Inventories | 145.4 m | 160.5 m | 161.1 m | esef· 21 Oct 2026verified |
| Current assets | 391.6 m | 429.1 m | 477.7 m | esef· 21 Oct 2026verified |
| Property, plant & equipment, net | 57.3 m | 71.8 m | 79.4 m | esef· 21 Oct 2026verified |
| Total assets | 505.7 m | 575.0 m | 660.6 m | esef· 21 Oct 2026verified |
| Current liabilities | 94.3 m | 107.4 m | 143.2 m | esef· 21 Oct 2026verified |
| Total liabilities | 107.8 m | 138.4 m | 192.2 m | esef· 21 Oct 2026verified |
| Equity | 397.9 m | 436.6 m | 468.4 m | esef· 21 Oct 2026verified |
| Shares outstanding at year end | 18.3 m | 18.3 m | 18.3 m | esef· 21 Oct 2026derived |
Cash flow · NOK
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 119.2 m | 143.1 m | 187.1 m | esef· 21 Oct 2026verified |
| Capex | 16.4 m | 6.1 m | 5.5 m | esef· 21 Oct 2026verified |
| Free cash flow | 102.8 m ≈ | 137.0 m ≈ | 181.6 m ≈ | esef· 21 Oct 2026derived |
| Investing cash flow | -29.7 m | -24.7 m | -33.0 m | esef· 21 Oct 2026verified |
| Financing cash flow | -90.9 m | -91.5 m | -123.5 m | esef· 21 Oct 2026verified |
| Dividends paid | 82.2 m | 82.4 m | 109.5 m | esef· 21 Oct 2026verified |
| Share repurchases | — | 0 | 4.7 m | esef· 21 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 52.1% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
06 Nov 2026Source: olivLaw, closing series
Market cap: 5.6 bn NOK
Key indicators
Coverage and freshness
Score by group
52% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 52.1% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 22.8% | 92 (vs peers) | 12% |
| FCF conversion · Quality | 114.1% | 100 (on a fixed band) | 12% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 11.6x | 100 (on a fixed band) | 12% |
| Current ratio · Balance sheet | 3.3x | 100 (on a fixed band) | 8% |
| P/E (TTM) · Valuation | 35.1x | 25 (vs peers) | 20% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 3.2% | 41 (on a fixed band) | 16% |
| Shareholder yield (distributions) · Returns | 2.0% | 29 (on a fixed band) | 12% |
| Payout ratio (FCF) · Returns | 60.3% | 85 (on a fixed band) | 8% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality96/100 · 2/3 factors with a value
- Returns52/100 · 2/2 factors with a value
- Valuation32/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
MEDISTIM ASA (MEDI.OL). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 699.8 m NOK in 2025; YoY growth 24.4%; net margin 22.8%; ROE 35.2%.
The estimated value range is 69.31–173.94 NOK per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 118.57 NOK, the price of 306.00 NOK leaves a potential of -61.3% (value / price − 1) and a margin of safety of -158.1% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 52.1% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 22.8%
- FCF conversion: 114.1%
- Interest coverage: 11.6x
- Current ratio: 3.3x
- Payout ratio (FCF): 60.3%
What contradicts it
- P/E (TTM): 35.1x
- Shareholder yield (distributions): 2.0%
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA.
Versus the vertical median
Listed companies from Norway · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AKER.OLAker Asa | 79.8 bn | 20.3 | 7.9% | 21.4% | +42.5% | +36% / +59% |
| AFG.OLAf Gruppen Asa | 21.5 bn | 19.8 | 39.7% | 3.4% | +4.4% | +8% / +69% |
| ELK.OLElkem Asa | 19.2 bn | 39.3 | 1.9% | 2.7% | −15.7% | +10% / +73% |
| ATEA.OLAtea Asa | 18.5 bn | 21.4 | 19.7% | 2.3% | +8.1% | +11% / +36% |
| AKSO.OLAker Solutions Asa | 17.4 bn | 6.8 | 22.5% | 4.1% | +19.2% | +18% / −12% |
| AUSS.OLAustevoll Seafood Asa | 16.6 bn | 37.1 | 1.6% | 1.1% | +11.1% | −7% / +10% |
| BRG.OLBorregaard Asa | 15.6 bn | 25.1 | 11.4% | 8.0% | +1.3% | −18% / −9% |
| BONHR.OLBonheur ASA | 11.2 bn | 7.8 | 17.1% | 11.4% | −10.8% | +17% / +44% |
| AFK.OLArendals Fossekompani Asa | 10.3 bn | — | -2.3% | -3.1% | −14.9% | +39% / +31% |
| B2I.OLB2 Impact Asa | 8.8 bn | 14.3 | 11.0% | 16.4% | +2.6% | +40% / +238% |
| AKVA.OLAkva Group Asa | 5.7 bn | 31.2 | 13.7% | 4.2% | +24.4% | +74% / +152% |
| MEDI.OLMedistim Asa | 5.6 bn | 35.1 | 35.2% | 22.8% | +24.4% | +22% / +51% |
| ELMRA.OLElmera Group Asa | 5.1 bn | 32.0 | 10.5% | 1.3% | −0.9% | +32% / +98% |
| BOUV.OLBouvet Asa | 5.0 bn | 14.2 | 80.7% | 9.2% | −0.2% | −19% / −16% |
| CLOUD.OLCloudberry Clean Energy Asa | 4.0 bn | 61.9 | 1.3% | 13.1% | +34.0% | −5% / +29% |
| ABG.OLAbg Sundal Collier Holding Asa | 3.6 bn | 10.7 | 34.9% | 16.8% | +12.4% | −13% / +20% |
| ANDF.OLAndfjord Salmon Group As | 2.2 bn | — | -5.7% | -12,770.4% | +328.9% | −18% / −11% |
| BMA.OLByggma Asa | 1.6 bn | — | -25.3% | -11.9% | −2.5% | +61% / +15% |
| APR.OLAppear Asa | 1.4 bn | 10.5 | 30.1% | 16.1% | +32.3% | −53% / unavailable |
| AZT.OLArcticzymes Technologies Asa | 1.1 bn | 108.9 | 2.9% | 8.6% | +7.9% | −8% / −48% |
| CAPSL.OLCapsol Technologies Asa | 884.6 m | — | -89.4% | -114.8% | −25.0% | −33% / −66% |
| BOR.OLBorgestad Asa | 553.2 m | 36.1 | 2.1% | 1.4% | −3.0% | −7% / +41% |
| ARR.OLArribatec Group Asa | 234.6 m | 4.8 | 22.1% | 9.3% | +15.7% | −33% / −55% |
| DELIA.OLDellia Group Asa | 73.5 m | 1.5 | 22.6% | 7.7% | +140.0% | −62% / unavailable |
| ABTEC.OLAqua Bio Technology Asa | 11.1 m | 0.1 | — | 7,297.7% | −87.2% | −82% / −97% |
1- and 3-year price returns: for MEDI.OL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (NOK)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 199.96 Total return -33% · Per year -33% | 351.90 Total return 17% · Per year 17% | 527.85 Total return 75% · Per year 75% |
| 3 years | 237.18 Total return -17% · Per year -6% | 465.39 Total return 60% · Per year 17% | 760.10 Total return 158% · Per year 37% |
| 5 years | 281.34 Total return 2% · Per year 0% | 615.48 Total return 116% · Per year 17% | 1,094.55 Total return 278% · Per year 30% |
- Exit P/E± 116.35
- Net margin± 81.44
- Annual revenue growth± 60.74
- Annual dilution± 6.84
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202521 Oct 2026
- Annual report 202408 May 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.